Zacks Company Profile for Paratek Pharmaceuticals, Inc. (PRTK : NSDQ) |
|
|
|
Company Description |
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Number of Employees: 208 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.97 |
Daily Weekly Monthly
 |
20 Day Moving Average: 558,569 shares |
Shares Outstanding: 54.48 (millions) |
Market Capitalization: $107.32 (millions) |
Beta: 1.57 |
52 Week High: $11.24 |
52 Week Low: $1.79 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-15.81% |
-7.75% |
12 Week |
-47.61% |
-43.15% |
Year To Date |
-56.13% |
-47.83% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Evan Loh - Chief Executive Officer and Director
Michael F. Bigham - Executive Chairman
Sarah Higgins - Vice President; Finance and Controller
Minnie V. Baylor Henry - Director
Thomas J. Dietz - Director
|
|
Peer Information
Paratek Pharmaceuticals, Inc. (CORR.)
Paratek Pharmaceuticals, Inc. (RSPI)
Paratek Pharmaceuticals, Inc. (CGXP)
Paratek Pharmaceuticals, Inc. (BGEN)
Paratek Pharmaceuticals, Inc. (GTBP)
Paratek Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 699374302
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
|
|
Share - Related Items
Shares Outstanding: 54.48
Most Recent Split Date: 10.00 (0.08:1)
Beta: 1.57
Market Capitalization: $107.32 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.71 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/08/22 |
|
|
|
|